Considering the efficacy of aromatase-inhibitor hormone therapy against breast cancer, it is necessary to evaluate, by means of prospective studies, whether an appropriate control program for cardiovascular risk factors can improve the prognosis. The gene discussed is CYP19A1; the disease is breast cancer.